Lilly to present more than 50 studies at oncology conference
INDIANAPOLIS The cancer drug arm of Eli Lilly plans to show data from more than 50 studies at the annual meeting of the American Society of Clinical Oncology in Chicago next month, Lilly said Monday.
Lilly Oncology’s presentations will include data from studies of Alimta (pemetrexed), Gemzar (gemcitabine hydrochloride) and Erbitux (cetuximab), which it will present with partners Bristol-Myers Squibb and German drug maker Merck-Serono, a separate company from U.S.-based Merck. Lilly acquired rights to Erbitux when it acquired ImClone Systems in 2008.
“Lilly Oncology research teams around the world are committed to finding new ways to improve and prolong the lives of people living with cancer,” Lilly Oncology president John Johnson said. “We are constantly studying new uses for our established therapies and discovering new molecules – all in the hopes of changing the way we treat cancer.”
The company placed particular emphasis on a phase 2 trial of Alimta combined with platinum-based chemotherapy in patients with advanced non-small cell lung cancer and also will present studies on such investigational cancer drugs as ramucirumab and cixutumumab, made by ImClone, and tasisulam.
Teva receives tentative approval for generic Sensipar
JERUSALEM The Food and Drug Administration has granted tentative approval to Teva Pharmaceutical Industries’ generic version of an Amgen drug, Teva said Friday.
The FDA gave the tentative approval to cincacalcet hydrochloride tablets in the 30-mg, 60-mg and 90-mg strengths. The drug is a generic version of Amgen’s Sensipar, which has annual sales of $458 million, according to IMS Health. The drug is used to treat secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
Tentative approval means that the drug meets most of the conditions for approval, but the FDA cannot grant final approval because the patents covering the drug don’t expire until December 2016, according to FDA records. Teva and Amgen are currently involved in patent litigation concerning the drug in the U.S. District Court for the District of Delaware, though a trial has not been set, Teva said.
RediClinic introduces Teen Health Package
HOUSTON RediClinic is launching in time for summer camp and upcoming school sports a new health package designed specifically for teenagers.
The new Teen Health Package includes a physical exam, an acne consultation and an immunization review for $59.
"We all know that adolescence is a time of great change," stated Susan Cooley King, VP clinical services. "With this in mind, RediClinic created a special health package that addresses the specific health needs of a teen."
Physical exams are always in season. They are required by summer camps and for participation in school sports. During a RedlClinic physical, a clinician evaluates the teen’s medical history. The exam is then performed, checking their physical health including, but not limited to, chest and heart, lymph nodes, blood pressure and abdomen.
Patients of the Teen Health Package also will receive an evaluation of their acne issues and the clinician will make recommendations for the most appropriate treatment ranging from over-the-counter medications to prescriptions.
According to the American Academy of Dermatology, 85% of American teenagers are effected by acne.
Patients also will receive an immunization review whereby the clinician will review the teen’s immunization history, identify which vaccines the patient needs for school admission and administer the vaccines, for an additional charge if necessary.